Actionable news
0
All posts from Actionable news
Actionable news in LPCN: LIPOCINE INC,

Regulation FD

The Company will present data from its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) evaluating efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with low testosterone ("Low T") at the 21st Annual Meeting of the Sexual Medicine Society of North America ("SMSNA") in Las Vegas, NV. The Companys materials to be used in the...


More